The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

Nadia Warner, Stephen Locarnini – 20 June 2008 – The hepatitis B virus (HBV) mutation that encodes rtA181T is selected in the viral polymerase during antiviral drug therapy and can also encode a stop codon in the overlapping surface gene at amino acid 172 (sW172*) resulting in truncation of the last 55 amino acids of the C‐terminal hydrophobic region of the surface proteins. This mutation is usually detected as a mixed population with wild‐type HBV.

Retinol‐binding protein 4: A new marker of virus‐induced steatosis in patients infected with hepatitis c virus genotype 1

Salvatore Petta, Calogero Cammà, Vito Di Marco, Nicola Alessi, Francesco Barbaria, Daniela Cabibi, Rosalia Caldarella, Stefania Ciminnisi, Anna Licata, Maria Fatima Massenti, Alessandra Mazzola, Giuseppe Tarantino, Giulio Marchesini, Antonio Craxì – 20 June 2008 – Retinol‐binding protein 4 (RBP4) is an adipocytokine associated with insulin resistance (IR). We tested serum levels of RBP4 to assess its link with steatosis in patients with genotype 1 chronic hepatitis C (CHC) or nonalcoholic fatty liver disease (NAFLD).

Subscribe to